trending Market Intelligence /marketintelligence/en/news-insights/trending/IL5ScXdnlU-QCaY5ofrgpw2 content esgSubNav
Log in to other products


Looking for more?

Contact Us
In This List

Osmotica Pharmaceuticals adds board member


COVID-19 Impact & Recovery: Healthcare Outlook for H2 2021


Climate Credit Analytics: Linking climate scenarios to financial impacts


Global M&A Infographic Q1 2021


Q1 2021 Global Capital Markets Activity: SPAC IPOs, Issuance in Consumer Discretionary Sector Surge

Osmotica Pharmaceuticals adds board member

Osmotica Pharmaceuticals PLC appointed Gregory Cowan to its board of directors and audit committee, effective Jan. 2, 2019.

Cowan previously served as executive vice president and CFO of Avantor Inc.

Bridgewater, N.J.-based Osmoticsa develops specialty products for underserved patient populations. Its products include M-72 for attention deficit hyperactivity disorder and Osmolex ER for Parkinson's and drug-induced extrapyramidal reactions in adults.